Peger Biotech announced that the company signed a memorandum of understanding with the US NASDAQ listed company Rani Therapeutics Holdings, Inc. on July 8, 2026. According to the memorandum of understanding, the two sides plan to rely on Rani's proprietary Ranipill oral biopharmaceutical delivery platform to carry out oral formulation screening and pre-clinical development around Peger Biotech's many innovative candidate assets for obesity and metabolic diseases, and further explore R&D, production and commercialization cooperation for related products in markets other than China with the goal of promoting the most promising candidate projects into clinical development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.